Lua Wilkinson

Lua Wilkinson

Auto-generated profile, based on publicly available information

Lua Wilkinson

Medical Affairs Novo Nordisk Inc. Plainsboro New Jersey USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2020 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
LWLua Wilkinson
Lua Wilkinson
NYNengjun Yi
Nengjun Yi
TMTapan Mehta
Tapan Mehta
SJSuzanne Judd
Suzanne Judd
WGW. Timothy Garvey
W. Timothy Garvey
Obesity is closely related to the development of insulin resistance and type 2 diabetes (T2D). The prevention of T2D has become imperative to stem the rising rates of this disease. Weight loss is highly effective in preventing T2D; however, the at-risk pool is large, and a clinically meaningful metric for risk stratification to guide interventions remains a challenge. The objective of this study is to predict T2D risk using full-information continuous analysis of nationally sampled data from white and black American adults age ≥45 years. A sample of 12,043 black (33%) and white individuals from a population-based cohort, REasons for Geographic And Racial Differences in Stroke (REGARDS) (enrolled 2003–2007), was observed through 2013–2016. The mean participant age was 63.12 ± 8.62 years, and 43.7% were male. Mean BMI was 28.55 ± 5.61 kg/m2. Risk factors for T2D regularly recorded in the primary care setting were used to evaluate future T2D risk using Bayesian logistic regression. External validation was performed using 9,710 participants (19% black) from Atherosclerotic Risk in Communities (ARIC) (enrolled 1987–1989), observed through 1996–1998. The mean participant age in this cohort was 53.86 ± 5.65 years, and 44.6% were male. Mean BMI was 27.15 ± 4.92 kg/m2. Predictive performance was assessed using the receiver operating characteristic (ROC) curves and area under the curve (AUC) statistics. The primary outcome was incident T2D. By 2016 in REGARDS, there were 1,602 incident cases of T2D. Risk factors used to predict T2D progression included age, sex, race, BMI, triglycerides, high-density lipoprotein, blood pressure, and blood glucose. The Bayesian logistic model (AUC = 0.79) outperformed the Framingham risk score (AUC = 0.76), the American Diabetes Association risk score (AUC = 0.64), and a cardiometabolic disease system (using Adult Treatment Panel III criteria) (AUC = 0.75). Validation in ARIC was robust (AUC = 0.85). Main limitations include the limited generalizability of the REGARDS sample to black and white, older Americans, and no time to diagnosis for T2D. Our results show that a Bayesian logistic model using full-information continuous predictors has high predictive discrimination, and can be used to quantify race- and sex-specific T2D risk, providing a new, powerful predictive tool. This tool can be used for T2D prevention efforts including weight loss therapy by allowing clinicians to target high-risk individuals in a manner that could be used to optimize outcomes.

22 August 2023 in Obesity
Verified
Journal Article
Open access
LWLua Wilkinson
Lua Wilkinson
THThomas Holst‐Hansen
Thomas Holst‐Hansen
PLPeter N. Laursen
Peter N. Laursen
ARAnders R. Rinnov
Anders R. Rinnov
RBRachel L. Batterham
Rachel L. Batterham
WGW. Timothy Garvey
W. Timothy Garvey
Objective: In the Semaglutide Treatment Effect in People with obesity (STEP) trials, once‐weekly subcutaneous semaglutide 2.4 mg plus lifestyle intervention reduced body weight and improved cardiometabolic parameters in adults with obesity (or overweight with weight‐related comorbidities). Effects on the risk of developing type 2 diabetes (T2D) require investigation.Methods: STEP 1 (68 weeks) and 5 (104 weeks) randomized participants to semaglutide 2.4 mg or placebo. STEP 4 included a 20‐week semaglutide run‐in followed by randomization to 48 weeks of continued semaglutide or withdrawal (placebo). Ten‐year T2D risk scores were calculated post hoc using Cardiometabolic Disease Staging.Results: In STEP 1 (N = 1583), relative risk score reductions were greater with semaglutide versus placebo (semaglutide: −61.1%; placebo: −12.9%; p < 0.0001). These reductions were maintained to week 104 in STEP 5 (N = 295; semaglutide: −60.0%; placebo: 3.5%; p < 0.0001). Risk scores during the STEP 4 run‐in period (N = 776) were reduced from 20.6% to 11.1% and further to 7.7% at week 68 with continued semaglutide, increasing to 15.4% with withdrawal (relative risk score change: semaglutide: −32.1%; placebo: +40.6%; p < 0.0001). Risk score reductions mirrored weight loss.Conclusions: Cardiometabolic Disease Staging risk assessment suggests that once‐weekly semaglutide 2.4 mg may substantially lower 10‐year T2D risk in people with overweight or obesity. image

19 September 2017 in Journal of Obesity
Verified
Journal Article
Open access
PDF file
LWLua Wilkinson
Lua Wilkinson
CPCarly Pacanowski
Carly Pacanowski
DLDavid Levitsky
David Levitsky
Frequent self-weighing is associated with weight loss maintenance. Several years ago, we investigated frequent self-weighing’s effect on weight loss and found the participants lost a significant amount of weight. Three years after this trial's end, participants were contacted for an update on their weight and self-weighing frequency. Weight change and self-weighing frequency since the end of the study were assessed. We hypothesized that participants who maintained frequent self-weighing behavior would have maintained their weight loss. Out of 98 participants enrolled in the RCT, 37% (n = 36) participated in this follow-up study. Total weight loss during the trial for the follow-up participants was 12.7 ± 19.4 lbs (p<0.001). Three years after intervention, participants regained 0.9 ± 4.34 lbs, a value that was not statistically different from zero (p=0.75). This did not differ by gender (p=0.655). Over 75% of these participants continued to weigh themselves at least once a week. Frequent self-weighing may be an effective, low-cost strategy for weight loss maintenance. Future research should further investigate the role of self-weighing in long-term weight gain prevention.